NCT03532854 is a Phase 1 clinical trial of Valsartan in Healthy Male Volunteers, sponsored by LG Chem.

Who is sponsoring NCT03532854?

NCT03532854 is sponsored by LG Chem.

What drugs are being tested in NCT03532854?

Interventions in NCT03532854: Valsartan, Ezetimibe/Rosuvastatin.

What condition does NCT03532854 study?

NCT03532854 studies Healthy Male Volunteers.

Is NCT03532854 still recruiting?

NCT03532854 is currently completed. Last updated 15 February 2019.

Last reviewed 2019-02-15 · How we verify

NCT03532854

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802

Completed Phase 1 Last updated 15 February 2019

What this trial tests

Phase 1 trial testing Valsartan in Healthy Male Volunteers in 42 participants. Completed in 30 January 2019.

Timeline

28 May 2018

Primary endpoint
25 August 2018

30 January 2019

Quick facts

Lead sponsor	LG Chem
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	28 May 2018
Primary completion	25 August 2018
Estimated completion	30 January 2019
Sites	1 location across South Korea

Drugs / interventions tested

Valsartan (VALSARTAN) — full drug profile →
Ezetimibe/Rosuvastatin — full drug profile →

Conditions studied

Healthy Male Volunteers — all drugs for Healthy Male Volunteers →

Sponsor

LG Chem — full company profile →

Who can join

Adults 19 to 50, male only, with Healthy Male Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the drug-drug interaction between LGEV1801 and LGEV1802 in healthy male volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Valsartan

Trials testing the same drug.

NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting
NCT07491718 — Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy · NA · recruiting
NCT06771245 — A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensi · Phase 3 · not yet recruiting
NCT06643819 — Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A · Phase 3 · recruiting
NCT06501651 — Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy · Phase 4 · not yet recruiting

Other recruiting trials for Healthy Male Volunteers

Currently open trials in the same condition.

NCT07479745 — Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019 · Phase 1 · recruiting

Other LG Chem trials

Trials by the same sponsor.

NCT07396844 — The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Voluntee · Phase 1 · not yet recruiting
NCT07399470 — A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagl · Phase 1 · active not recruiting
NCT07333742 — A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metfor · Phase 1 · completed
NCT06921395 — Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulat · Phase 4 · recruiting
NCT06743997 — A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03532854 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LG Chem
Last refreshed: 15 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03532854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing